Due to the strength of its positioning in generic drugs and its world-renowned quality standards, Pharma 5 has developed a commercial policy that takes it beyond its territorial borders.
Present in Africa and the Middle East, Pharma 5 products attract regional and international markets by their quality and therapeutic diversity (more than 400 specialties).
To consolidate its export positioning, Pharma 5 has planned the opening of several sales offices, notably in Senegal, Cameroon, Cote d’Ivoire, Algeria and Saudi Arabia.
Other markets are targeted by Pharma 5, which, always with a view to presenting quality products, aims to obtain approval from the American FDA (Food and Drug Administration) and the ANSM (Agence Nationale de Sécurité du Médicament).
A NEW IMPLANTATION IN IVORY COAST
The Pharma 5 laboratory is pursuing its development plan in Morocco and internationally by launching the construction of a first industrial site in Abidjan, Ivory Coast.
In December 2017, Pharma 5 laid the foundation stone of an industrial unit in Ivory Coast which will extend over an area of 1.5 hectares with an initial investment of MAD 100 million allocated to infrastructure and equipment.
This new investment shall create 200 direct jobs (20% of which will be managerial) and 2,000 indirect jobs to meet the needs of the Ivorian population for medicines at affordable prices. Initially, this industrial unit will produce medicines in 5 therapeutic classes: infectiology, virology, gynecology, analgesia and antibiotics.
This new unit aims to produce up to 100 million tablets and 10 million sachets per year.
In a second phase, the new unit aims to develop the export of its drugs to countries in the sub-region by acting as a regional hub with an effective start of activity for this project scheduled for 2019. The launch of this new industrial site thus confirms the African ambitions of the Pharma 5 group and the excellent relations of friendship, solidarity and cooperation that bind Morocco and Ivory Coast.